Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer

Excluded: BRCA1 germline mutation

Excluded: BRCA2 germline mutation

Cannot have received: radiotherapy

Exception: no overlap between the secondary radiotherapy site and the original radiotherapy site

No previous history of radiotherapy or no overlap between the secondary radiotherapy site and the original radiotherapy site

Cannot have received: agent targeting T cell costimulation or immune checkpoint pathways (anti-PD 1, anti-PD L1, anti-PD L2, anti-CTLA 4, anti-CD137, anti-OX40 antibody)

Prior exposure to any agent targeting T cell costimulation or immune checkpoint pathways (e.g., anti-PD 1, anti-PD L1, anti-PD L2, anti-CTLA 4, anti CD137 or anti-OX40 antibody, etc)

Cannot have received: chemotherapy

Received chemotherapy...within 28 days before the study

Cannot have received: tyrosine kinase inhibitor

Received...tyrosine kinase inhibitors...within 28 days before the study

Cannot have received: immunotherapy (interleukin, interferon, thymosin)

Received...immunotherapy (such as interleukin, interferon or thymosin)...within 28 days before the study

Cannot have received: other anti-tumor therapy

Received...other anti-tumor therapy within 28 days before the study

Cannot have received: Chinese medicine with anti-tumor indications

received Chinese medicine with anti-tumor indications within 14 days before the administration

Cannot have received: major surgery

Has undergone major surgery within 30 days prior to the first dose of study treatment

Cannot have received: radical radiotherapy

Exception: Palliative radiotherapy was allowed 2 weeks before administration, and the radiotherapy dose was in line with local palliative treatment standards

Has received radical radiotherapy within 3 months before the study; Palliative radiotherapy was allowed 2 weeks before administration, and the radiotherapy dose was in line with local palliative treatment standards